| Reference : Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial |
| Scientific journals : Article | |||
| Human health sciences : Multidisciplinary, general & others | |||
| http://hdl.handle.net/10993/26953 | |||
| Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial | |
| English | |
| Knip, M. [> >] | |
| Åkerblom, H.K. [> >] | |
| Becker, D. [> >] | |
| Dosch, H.M. [> >] | |
| Dupre, J. [> >] | |
| Fraser, W. [> >] | |
| Howard, N. [> >] | |
| Ilonen, J. [> >] | |
| Krischer, J.P. [> >] | |
| Kordonouri, O. [> >] | |
| Lawson, M.L. [> >] | |
| Palmer, J.P. [> >] | |
| Savilahti, E. [> >] | |
| Vaarala, O. [> >] | |
| Virtanen, S.M. [> >] | |
De Beaufort, Carine  [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > >] | |
| 11-Jun-2014 | |
| JAMA: Journal of the American Medical Association | |
| American Medical Association | |
| 311 | |
| 22 | |
| 2279-2287 | |
| Yes (verified by ORBilu) | |
| 0098-7484 | |
| 1538-3598 | |
| Chicago | |
| IL | |
| [en] hydrolyzed infant formula ; Hydrolyzed infant formula and early β-cell autoimmunity | |
| [en] Importance The disease process leading to clinical type 1 diabetes often starts during the first years of life. Early exposure to complex dietary proteins may increase the risk of β-cell autoimmunity in children at genetic risk for type 1 diabetes. Extensively hydrolyzed formulas do not contain intact proteins.
Objective To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of diabetes-associated autoantibodies in young children. Design, Setting, and Participants A double-blind randomized clinical trial of 2159 infants with HLA-conferred disease susceptibility and a first-degree relative with type 1 diabetes recruited from May 2002 to January 2007 in 78 study centers in 15 countries; 1078 were randomized to be weaned to the extensively hydrolyzed casein formula and 1081 were randomized to be weaned to a conventional cows’ milk–based formula. The participants were observed to April 16, 2013. Interventions The participants received either a casein hydrolysate or a conventional cows’ milk formula supplemented with 20% of the casein hydrolysate. Main Outcomes and Measures Primary outcome was positivity for at least 2 diabetes-associated autoantibodies out of 4 analyzed. Autoantibodies to insulin, glutamic acid decarboxylase, and the insulinoma-associated–2 (IA-2) molecule were analyzed using radiobinding assays and islet cell antibodies with immunofluorescence during a median observation period of 7.0 years (mean, 6.3 years). Results The absolute risk of positivity for 2 or more islet autoantibodies was 13.4% among those randomized to the casein hydrolysate formula (n = 139) vs 11.4% among those randomized to the conventional formula (n = 117). The unadjusted hazard ratio for positivity for 2 or more autoantibodies among those randomized to be weaned to the casein hydrolysate was 1.21 (95% CI, 0.94-1.54), compared with those randomized to the conventional formula, while the hazard ratio adjusted for HLA risk, duration of breastfeeding, vitamin D use, study formula duration and consumption, and region was 1.23 (95% CI, 0.96-1.58). There were no clinically significant differences in the rate of reported adverse events between the 2 groups. Conclusions and Relevance Among infants at risk for type 1 diabetes, the use of a hydrolyzed formula, when compared with a conventional formula, did not reduce the incidence of diabetes-associated autoantibodies after 7 years. These findings do not support a benefit from hydrolyzed formula. | |
| TRIGR Study Group | |
| http://hdl.handle.net/10993/26953 |
| File(s) associated to this reference | ||||||||||||||
|
Fulltext file(s):
| ||||||||||||||
All documents in ORBilu are protected by a user license.
